English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

he Institute for Advancing Medical Innovations (IAMI) was founded in January 2009 with an $8.1 million funding from the Kauffman foundation and a matching contribution from the University of Kansas Endowment Association. The $16.2 million funding for five years was targeted to: 1) advance novel, new medical innovations for the diagnosis, treatment, prevention and control of human and animal disease to clinical proof of concept, 2) create a culture of multidisciplinary, multi-organizational collaboration, and 3) prepare graduate and postdoctoral student for careers in development and commercialization of medical innovations. A staff of experienced project managers and management with over 100 years of pharmaceutical industry experience, and an external advisory board of experienced entrepreneurs and an adjunct faculty to mentor graduate fellows supports IAMI. Annual investment of $1.6 million is for proof-of concept (POC) projects initiated by KU faculty both at the Lawrence campus and the medical center in Kansas City. This investment is intended as a key differentiator for the National Cancer Institute (NCI) designation for the University of Kansas Cancer Center and the Clinical Translational Science Award currently under preparation.

The Institute of Advancing Medical Innovation (IAMI): Stepping into the future of academic research and entrepreneurship